Success stories in 2020 don’t come much more triumphant than that of molecular diagnostics player Co-Diagnostics (CODX). Shares are up by a barely believable 1,365% since the turn of the year. Yet, following a disappointing Q2 earnings report, the stock has pulled back by 45% over the past month. So, is now the right time to pull the trigger on CODX shares?H.C. Wainwright analyst Yi Chen certainly thinks so. Chen reiterated a Buy rating on the stock, alongside a $33 price target. The implication for investors? Potential upside of a massive 153% from current levels. (To watch Chen’s track record, …read more
Source:: Yahoo Finance
